FINWIRES · TerminalLIVE
FINWIRES

标普500指数和纳斯达克指数均创收新高后,美国股指期货盘前涨跌互现。

By

-- 周五美股期货开盘涨跌互现,此前标普500指数和纳斯达克综合指数均创下4月收盘新高,而中东局势仍持续僵持。 道琼斯工业平均指数期货上涨0.3%,标普500指数期货上涨0.1%,纳斯达克指数期货下跌0.2%。 周四,标普500指数上涨1%,收于7209.01点,首次突破7200点大关;纳斯达克指数上涨0.9%,收于24892.31点,同样创下新的收盘纪录。 据Axios周三报道,美国总统特朗普拒绝了伊朗的最新提议,并表示美国将继续封锁伊朗港口,直到伊朗政权同意一项能够解决美国对其核计划担忧的协议。 交易员们关注了最新一轮的财报,能源巨头埃克森美孚(XOM)和雪佛龙(CVX)均公布第一季度调整后盈利下降,但营收增长。 油价涨跌互现,近月全球基准北海布伦特原油上涨0.5%,至每桶110.95美元;美国西德克萨斯中质原油下跌0.8%,至每桶104.21美元。 彭博社汇总的预测显示,将于美国东部时间上午9:45公布的4月终值采购经理人制造业指数(PMI)预计将为54.0,与前值持平。 将于美国东部时间上午10:00公布的4月供应管理协会(ISM)服务业指数预计将为53.2,高于前值的52.7。

Related Articles

Research

Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.

$INCY
Australia

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%

$GSK
International

ISM US Manufacturing Index Indicates Steady Expansion in April

The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.